Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of ...

Citius Oncology (CTOR) said on Monday it has launched Lymphir, a newly approved cancer immunotherapy for adults with relapsed ...

Citius Oncology launches US FDA approved Lymphir, a novel cancer immunotherapy for cutaneous T-cell lymphoma: Cranford, New Jersey Wednesday, December 3, 2025, 16:00 Hrs [IST] Cit ...

(CNN) — An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. The ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.

Infections are the cause of more than half of all non-relapse-related deaths after chimeric antigen receptor T-cell immunotherapy for lymphoma and multiple myeloma patients, according to a study ...

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the ...

Treatment involved chemotherapy and immunotherapy, with side effects often more tolerable than those of other cancers. Feeling like others have it worse can dismiss the real challenges of follicular ...